Uric Acid and Cardiovascular Disease: An Update

Muiesan, María Lorenza; Agabiti-Rosei, Claudia; Paini, Anna; Salvetti, Massimo

doi:10.15420/ecr.2016:4:2

Cited by 87 publications

(72 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At physiological concentrations, urate reduces the oxo-heme oxidant formed by peroxide reaction with hemoglobin and protects both erythrocyte ghosts against lipid peroxidation and erythrocytes from peroxidative damage leading to lysis [34]. In contrast, high urate levels are a well-known strong risk factor for gout and renal calculi, as well as a triggering factor for metabolic syndrome and CVDs [35]. The lowest mean levels of urate found in the non-dipping group suggested that people who have this pathological pattern also have one less protective factor, if we consider uric acid useful for its antioxidant effects.…”

Section: Discussionmentioning

confidence: 99%

Uric Acid and Potassium Serum Levels Are Independent Predictors of Blood Pressure Non-Dipping in Overweight or Obese Subjects

et al. 2019

View full text Add to dashboard Cite

Background: Obesity and sleeping blood pressure (BP) abnormalities are well recognized as some of the main risk factors for hypertension and cardiovascular diseases (CVDs). The primary objective of this study was to evaluate the prevalence of hypertension and non-dipping profile in overweight/obese subjects. Methods: A sample of 100 consecutive healthy overweight/obese subjects, aged 20–69 years and never treated with antihypertensive drugs was examined. Ambulatory 24 h BP monitoring was performed to diagnose hypertension and a non-dipping profile. Anthropometric, metabolic and routine hematochemical parameters were assessed. All subjects underwent ultrasound measurement of common carotid intima–media thickness. Results: Hypertension was demonstrated in 69% (n = 69) and 27% of the sample (n = 27) had a non-dipping profile. Among the hematochemical variables, estimated glomerular filtration rate (eGFR) (p = 0.02) and FT4 (p = 0.01) serum levels were higher in the hypertensive group than in the normotensive group. Lower potassium and uric acid serum levels (p = 0.05) were independent predictive factors of a non-dipping BP profile. Conclusions: This study shows, for the first time, that 1) an unexpectedly high percentage (69%) of overweight/obese subjects is affected by hypertension; 2) early hypertensive subjects have an increased eGFR and higher FT4 serum levels; 3) lower potassium and uric acid levels are independent predictors of pathological nocturnal non-dipping.

show abstract

Section: Discussionmentioning

confidence: 99%

Uric Acid and Potassium Serum Levels Are Independent Predictors of Blood Pressure Non-Dipping in Overweight or Obese Subjects

et al. 2019

View full text Add to dashboard Cite

show abstract

“…At present, there are conflicting reports on the association between sUA and CVD . The Framingham Heart Study, Sibutramine Cardiovascular Outcome (SCOUT) trial, Copenhagen cohort studies and an Italian population‐based survey found no association between sUA and CVD .…”

Section: Introductionmentioning

confidence: 99%

Hyperuricaemia and its association with 10‐year risk of cardiovascular disease among migrant and non‐migrant African populations: the RODAM study

Chilunga

Henneman

Requena‐Méndez

et al. 2020

Tropical Med Int Health

View full text Add to dashboard Cite

objective In the advent of rapid urbanisation, migration and epidemiological transition, the extent to which serum uric acid (sUA) affects cardiovascular disease (CVD) risk among Africans is not well understood. We assessed differences in sUA levels and associations with CVD risk among migrant Ghanaians in Europe and non-migrant Ghanaians in rural and urban Ghana.methods Baseline data from 633 rural, 916 urban and 2315 migrant participants (40-70 years) from the cross-sectional RODAM study were analysed. Hyperuricaemia was defined as sUA >7 mg/dl in men and >6 mg/dl in women. The 10-year risk of atherosclerotic cardiovascular disease (ASCVD) was calculated using the American College of Cardiology (ACC)/American Heart Association (AHA) risk score which takes into account ethnic minority populations. High CVD risk was defined as ASCVD risk scores ≥7.5%. Logistic regressions were used to assess associations between hyperuricaemia and CVD risk.results Prevalence for hyperuricaemia in rural, urban and migrant participants was 17.4%, 19.1% and 31.7% for men, and 15.9%, 18.2% and 33.2% for women, respectively. Hyperuricaemia was positively associated with elevated CVD risk among rural residents (adjusted OR for men 3.28, 95% CI: 1.21-8.96, 6.36, 95% CI: 2.98-13.56 for women), urban residents (1.12, 95% CI: 0.45-2.81 for men, 2.11, 95% CI: 1.26-3.52 for women) and migrants (1.73, 95% CI: 1.01-2.96 for men, 4.61, 95% CI: 3.05-6.97 for women).conclusion Our study shows variations of sUA levels in different African contexts. Hyperuricaemia is associated with elevated 10-year CVD risk in both migrants and non-migrants. Further studies should identify factors driving associations between sUA and CVD risk in Africans.keywords serum uric acid, cardiovascular disease risk, sub-Saharan Africans, migrants, Europe, RODAM study Sustainable Development Goals (SDGs): SDG 3 (good health and well-being), SDG 10 (reduced inequalities), SDG 17 (partnerships for the goals)

show abstract

“…However, only 5% of patients with hyperuricemia develop gout [2]. It has been seen that the disorder, either gout or hyperuricemia, has been associated with derangement of various metabolic parameters like microalbuminuria, dyslipidemia, nonalcoholic steatohepatitis, chronic kidney disease, and cardiovascular diseases [20][21][22][23][24].…”

Section: Discussionmentioning

confidence: 99%

Changes in Urinary Microalbumin Levels after Correction of Hyperuricemia in Patients with Gout: An Observational Cohort Study

Vaidya¹,

Pudasaini²,

Nakarmi³

2020

International Journal of Rheumatology

View full text Add to dashboard Cite

Background. Gout is commonly associated with metabolic syndrome. Strong association between the serum uric acid level and microalbuminuria has also been observed in various studies. Aim. To observe the change in urinary microalbumin after urate-lowering treatment in patients with gout and microalbuminuria. Methodology. A prospective, observational study was conducted at a tertiary-level rheumatic center (NCRD) in Kathmandu, Nepal. Adults diagnosed with gout using the 2015 ACR/EULAR criteria and microalbuminuria were enrolled in the study after obtaining informed consent. Sociodemographic profile and clinical history were recorded at baseline. Serum uric acid levels, spot urinary microalbumin (MAU) excretion, blood sugar, lipid profile, and blood pressure were measured at baseline, 3-month follow-up, and 6-month follow-up. A paired t-test was used to compare the change in mean MAU after treatment. Results. A total of 778 patients diagnosed with gout were screened for microalbuminuria. Among them, 114 (14.6%) had urinary microalbumin levels of >30.0 mg/L during presentation. Mean MAU level among those with microalbuminuria was 132.4±124.6 mg/L. Thirty-five patients had concomitant HTN and were put on ARBs (20 mg of telmisartan). All received 40 mg of febuxostat. In patients with ARBs, MAU reduced significantly after 3 months of treatment with ARBs. Reduction in MAU in those without ARBs was seen after the 6-month follow-up, and the change was statistically significant. Conclusions. There is significant reduction in MAU after the use of urate-lowering drugs in patients with gout.

show abstract

Uric Acid and Cardiovascular Disease: An Update

Cited by 87 publications

References 92 publications

Uric Acid and Potassium Serum Levels Are Independent Predictors of Blood Pressure Non-Dipping in Overweight or Obese Subjects

Uric Acid and Potassium Serum Levels Are Independent Predictors of Blood Pressure Non-Dipping in Overweight or Obese Subjects

Hyperuricaemia and its association with 10‐year risk of cardiovascular disease among migrant and non‐migrant African populations: the RODAM study

Changes in Urinary Microalbumin Levels after Correction of Hyperuricemia in Patients with Gout: An Observational Cohort Study

Contact Info

Product

Resources

About